Methods for biomarker verification and assay development

Yingxin Zhao, Allan R. Brasier

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Recent advances in global-scale proteomic technology enable identification of hundreds of candidate biomarkers. However, very few candidates so identified can reach the high bar of FDA approval for clinical use. The low efficiency of biomarker approval reflects the challenges of taking candidate biomarkers identified in discovery research through the long and difficult pipeline required for biomarker development. The greatest challenge in biomarker development is the lack of reliable assays for use in the verification and validation phases. This paper reviews methodologies and challenges for biomarker assay development with emphasis on stable isotope dilution coupled with multiple reaction monitoring-mass spectrometry (SID-MRM-MS). Because of its sensitivity, quantification abilities, and specificity, SIDMRM- MS has the potential to bridge the critical rate-limiting gaps between the biomarker discovery- and validation phases. A workflow for generation of a specific SID-MRM-MS assay is presented. We conclude that currently, SIDMRM- MS assay is a promising technology for biomarker verification and validation. To move the technology toward an FDA-approvable platform, more stringent evaluation must be performed and these future studies will require a joint effort of the clinical proteomics community, the regulatory agency and major mass spectrometer manufacturers.

Original languageEnglish (US)
Pages (from-to)138-152
Number of pages15
JournalCurrent Proteomics
Volume8
Issue number2
StatePublished - Jul 2011

Fingerprint

Biomarkers
Assays
Technology
Isotopes
Proteomics
Dilution
Mass spectrometry
Mass Spectrometry
Workflow
Monitoring
Mass spectrometers
Pipelines
Research

Keywords

  • Assay development
  • Biomarker verification
  • Mass spectrometry
  • Multiple reaction monitoring
  • Proteomics
  • Stable

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Methods for biomarker verification and assay development. / Zhao, Yingxin; Brasier, Allan R.

In: Current Proteomics, Vol. 8, No. 2, 07.2011, p. 138-152.

Research output: Contribution to journalArticle

Zhao, Y & Brasier, AR 2011, 'Methods for biomarker verification and assay development', Current Proteomics, vol. 8, no. 2, pp. 138-152.
Zhao, Yingxin ; Brasier, Allan R. / Methods for biomarker verification and assay development. In: Current Proteomics. 2011 ; Vol. 8, No. 2. pp. 138-152.
@article{0fc9796bff2e44d884fe46948c9e49e5,
title = "Methods for biomarker verification and assay development",
abstract = "Recent advances in global-scale proteomic technology enable identification of hundreds of candidate biomarkers. However, very few candidates so identified can reach the high bar of FDA approval for clinical use. The low efficiency of biomarker approval reflects the challenges of taking candidate biomarkers identified in discovery research through the long and difficult pipeline required for biomarker development. The greatest challenge in biomarker development is the lack of reliable assays for use in the verification and validation phases. This paper reviews methodologies and challenges for biomarker assay development with emphasis on stable isotope dilution coupled with multiple reaction monitoring-mass spectrometry (SID-MRM-MS). Because of its sensitivity, quantification abilities, and specificity, SIDMRM- MS has the potential to bridge the critical rate-limiting gaps between the biomarker discovery- and validation phases. A workflow for generation of a specific SID-MRM-MS assay is presented. We conclude that currently, SIDMRM- MS assay is a promising technology for biomarker verification and validation. To move the technology toward an FDA-approvable platform, more stringent evaluation must be performed and these future studies will require a joint effort of the clinical proteomics community, the regulatory agency and major mass spectrometer manufacturers.",
keywords = "Assay development, Biomarker verification, Mass spectrometry, Multiple reaction monitoring, Proteomics, Stable",
author = "Yingxin Zhao and Brasier, {Allan R.}",
year = "2011",
month = "7",
language = "English (US)",
volume = "8",
pages = "138--152",
journal = "Current Proteomics",
issn = "1570-1646",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Methods for biomarker verification and assay development

AU - Zhao, Yingxin

AU - Brasier, Allan R.

PY - 2011/7

Y1 - 2011/7

N2 - Recent advances in global-scale proteomic technology enable identification of hundreds of candidate biomarkers. However, very few candidates so identified can reach the high bar of FDA approval for clinical use. The low efficiency of biomarker approval reflects the challenges of taking candidate biomarkers identified in discovery research through the long and difficult pipeline required for biomarker development. The greatest challenge in biomarker development is the lack of reliable assays for use in the verification and validation phases. This paper reviews methodologies and challenges for biomarker assay development with emphasis on stable isotope dilution coupled with multiple reaction monitoring-mass spectrometry (SID-MRM-MS). Because of its sensitivity, quantification abilities, and specificity, SIDMRM- MS has the potential to bridge the critical rate-limiting gaps between the biomarker discovery- and validation phases. A workflow for generation of a specific SID-MRM-MS assay is presented. We conclude that currently, SIDMRM- MS assay is a promising technology for biomarker verification and validation. To move the technology toward an FDA-approvable platform, more stringent evaluation must be performed and these future studies will require a joint effort of the clinical proteomics community, the regulatory agency and major mass spectrometer manufacturers.

AB - Recent advances in global-scale proteomic technology enable identification of hundreds of candidate biomarkers. However, very few candidates so identified can reach the high bar of FDA approval for clinical use. The low efficiency of biomarker approval reflects the challenges of taking candidate biomarkers identified in discovery research through the long and difficult pipeline required for biomarker development. The greatest challenge in biomarker development is the lack of reliable assays for use in the verification and validation phases. This paper reviews methodologies and challenges for biomarker assay development with emphasis on stable isotope dilution coupled with multiple reaction monitoring-mass spectrometry (SID-MRM-MS). Because of its sensitivity, quantification abilities, and specificity, SIDMRM- MS has the potential to bridge the critical rate-limiting gaps between the biomarker discovery- and validation phases. A workflow for generation of a specific SID-MRM-MS assay is presented. We conclude that currently, SIDMRM- MS assay is a promising technology for biomarker verification and validation. To move the technology toward an FDA-approvable platform, more stringent evaluation must be performed and these future studies will require a joint effort of the clinical proteomics community, the regulatory agency and major mass spectrometer manufacturers.

KW - Assay development

KW - Biomarker verification

KW - Mass spectrometry

KW - Multiple reaction monitoring

KW - Proteomics

KW - Stable

UR - http://www.scopus.com/inward/record.url?scp=79958275039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958275039&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79958275039

VL - 8

SP - 138

EP - 152

JO - Current Proteomics

JF - Current Proteomics

SN - 1570-1646

IS - 2

ER -